索拉菲尼联合阿霉素治疗晚期肝细胞癌 - 第三军医大学学报.doc

肝动脉化疗栓塞联合索拉菲尼治疗晚期肝细胞癌 杨明施晓敏 傅志仁 通讯作者：施晓敏摘要 目的 探讨联合索拉菲尼治疗晚期肝细胞癌的临床价值。方法 回顾性分析我院20年1月至201年1月接受联合索拉菲尼400mg 口服bid的晚期患者的临床资料，采用SPSS13.0软件进行统计分析， Kaplan-Meier法患者肿瘤无进展生存率和总生存率。结果 患者最长随访时间个月，期间共发生肿瘤进展例（.7%）死亡例（.0%）。率为.1%。患者肿瘤中位进展时间为6.5个月（95%CI 5.9～7.1）中位肿瘤无进展生存时间为7.0个月（95%CI .0～.0）患者6-，12个月的肿瘤无进展生存率分别为%，.3%，总生存率分别为.0%，.8%。副作用为。 结论 本研究初步表明，联合索拉菲尼晚期 [关键词；索拉菲尼；肝细胞癌；预后 COMBINATION OF TRANSARTERIAL CHEMOEMBOLIZATION WITH SORAFENIB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (1. YANG Ming, LUO Kepin, XIE Yueyun, ZOU Tongxiang, Department of Oncology, 181 hospital of PLA, Guilin, Guangxi 541002; 2. SHI Xiaoming, FU Zhiren, Department of liver surgery, Changzheng hospital, Shanghai, Second Military Medical University, 200003.) [Abstract]　Objective To evaluate the value of combination of ransarterial chemoembolization (TACE) with sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods Between January 2011 and January 2012, twenty seven patients with unresectable HCC who were not candidates for potentially curative treatment in our department were enrolled for this retrospective analysis. Patients were administrated TACE once a month plus sorafenib at a dose of 800mg per day. SPSS13.0 software was used for statistical analysis. The Kaplan-Meier method was used to evaluate the median time to tumor progression, progression-free survival and overall survival rates. Results The longest time of follow-up were 12 months, with an overall tumor progression and mortality rate of 66.7% and 37.0%, respectively. The disease control rate was 74.1%, while the median time to tumor progression was 6.5 months (95%CI 5.9～7.1.0 months (95%CI 6.0～.0). The 6- and 12-month progression-free survival rates were 51.9% and 33.3%. The 6- and 12-month patient overall survival rates were 81.0% and 60.8%. The common side effects were post-TACE syndrome, elevated aminotransferase/bilirubin, hand-foot syndrome, fatigue and gastroenterological symptoms. Conclusion This preliminary